Literature DB >> 1527237

Reversible neurologic symptoms with clozapine and lithium.

L M Blake, R C Marks, D J Luchins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1527237

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  7 in total

Review 1.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 3.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

4.  Reversible lithium neurotoxicity: review of the literatur.

Authors:  Ivan Netto; Vivek H Phutane
Journal:  Prim Care Companion CNS Disord       Date:  2012

Review 5.  Clinical relevance of drug interactions with lithium.

Authors:  P R Finley; M D Warner; C A Peabody
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

6.  Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy.

Authors:  Vivekananda Rachamallu; Ayman Haq; Michael M Song; Manish Aligeti
Journal:  Case Rep Psychiatry       Date:  2017-08-01

7.  Medication-induced obstructive uropathy and hyperprolactinemia in a pediatric patient.

Authors:  Kwabena Nkansah-Amankra; Sathyanarayan Sudhanthar
Journal:  Clin Case Rep       Date:  2019-08-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.